11,479 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Purchased by Barclays PLC

Barclays PLC acquired a new position in Delcath Systems, Inc. (NASDAQ:DCTH) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,479 shares of the company’s stock, valued at approximately $104,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. purchased a new stake in Delcath Systems in the 3rd quarter worth about $1,594,000. Shellback Capital LP purchased a new position in shares of Delcath Systems during the second quarter worth approximately $1,353,000. Marshall Wace LLP increased its position in shares of Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after acquiring an additional 6,066 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Delcath Systems during the third quarter worth approximately $808,000. Finally, State Street Corp increased its position in shares of Delcath Systems by 12.4% during the third quarter. State Street Corp now owns 85,457 shares of the company’s stock worth $772,000 after acquiring an additional 9,400 shares during the period. 61.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DCTH has been the topic of a number of research reports. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Delcath Systems in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $12.06 on Thursday. The firm’s 50 day moving average price is $11.21 and its 200-day moving average price is $9.71. Delcath Systems, Inc. has a 52-week low of $3.70 and a 52-week high of $13.30. The company has a market cap of $385.61 million, a PE ratio of -8.93 and a beta of 0.87.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.